Total lesion glycolysis as the best F-18-FDG PET/CT parameter in differentiating intermediate-high risk adrenal incidentaloma

Nuclear Medicine Communications (Impact Factor: 1.37). 03/2014; 35(6). DOI: 10.1097/MNM.0000000000000101
Source: PubMed

ABSTRACT Characterization of intermediate-high risk adrenal incidentaloma (AI) is important because biopsy or surgery should be performed to confirm the malignancy. We investigated which parameters of F-fluorodeoxyglucose (F-FDG) PET/computed tomography (CT) had an additive role in distinguishing malignancies in patients with incidental adrenal masses of intermediate-high risk.
From January 2008 to July 2013, 52 patients with a pathologically proven diagnosis of AI were retrospectively enrolled (age=56.4±12.7 years, M : F=34 : 18; benign : malignant=14 : 38). Volumetric parameters were size and volume according to combined CT, and metabolic parameters were peak standardized uptake value (SUVpeak), maximum SUV (SUVmax), mean SUV (SUVmean), and tumor-to-background ratio (SUVmax of adrenal mass/SUVmean of liver). Metabolovolumetric parameters of metabolic tumor volume and total lesion glycolysis (TLG, SUVmean×metabolic tumor volume) were also included and compared with the diagnostic value. In addition, the highest diagnostic parameters among volumetric and metabolic parameters were combined and compared in terms of diagnostic accuracy.
Compared with benign adrenal adenoma, malignant lesions showed significantly higher values of all F-FDG PET/CT volumetric, metabolic, and metabolovolumetric parameters. Size showed the highest area under the curve (AUC) of 0.759 among the volumetric parameters, and SUVpeak showed the highest AUC of 0.853 among the metabolic parameters. Among all the PET/CT parameters, TLG showed the highest AUC of 0.900, with a sensitivity of 92.1% and specificity of 78.6% at a cutoff of 12.0. The combined value of size and SUVpeak showed lower diagnostic value than TLG.
We found that TLG showed the best result in distinguishing intermediate-high risk AI among PET/CT parameters. TLG can be a useful PET/CT parameter for differential diagnosis of AI.

Download full-text


Available from: Gi Jeong Cheon, Apr 17, 2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Image quantification studies in positron emission tomography/computed tomography (PET/CT) are of immense importance in the diagnosis and follow-up of variety of can-cers. In this review we have described the current image quantification methodologies employed in 1 8 F-fluorodeoxyglucose (18 F-FDG) PET in major oncological conditions with particular emphasis on tumor heterogeneity studies. We have described various quantitative parameters being used in PET image analysis. The main contemporary methodology is to measure tumor metabolic activity; howev-er, analysis of other image-related parameters is also increas-ing. Primarily, we have identified the existing role of tumor heterogeneity studies in major cancers using 18 F-FDG PET. We have also described some newer radiopharmaceuticals other than 18 F-FDG being studied/used in the management of these cancers. Tumor heterogeneity studies are being per-formed in almost all major oncological conditions using 18 F-FDG PET. The role of these studies is very prom-ising in the management of these conditions.
    Nuclear Medicine and Molecular Imaging 01/2014; 48(1):1-15. DOI:10.1007/s13139-013-0260-2
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: OBJECTIVE: Adrenal nodules are frequently encountered on current high-resolution imaging, and accurate characterization of such lesions is critical for appropriate patient care. Our article highlights how imaging techniques such as CT densitometry, CT washout characteristics, chemical shift MRI, PET, and PET/CT help characterize most adrenal lesions. We focus on these techniques as well as specifically, because of space constraints, the varied imaging appearances of adrenocortical carcinoma, pheochromocytoma, and lymphoma on these techniques. CONCLUSION: The imaging characterization of adrenal lesions has continued to advance over the past decade as new technologies have evolved. CT, MRI, PET, and PET/CT are now established clinical techniques capable of differentiating benign from malignant adrenal lesions.
    American Journal of Roentgenology 06/2010; 194(6):1450-60. DOI:10.2214/AJR.10.4547 · 2.74 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Adrenal metastasis in renal cell carcinoma (RCC) is uncommon. The present study was aimed to evaluate the role of fluoro-deoxy-glucose positron emission tomography (FDG PET)/computed tomography (CT) in the detection of adrenal metastasis in patients with RCC. A total of 9 FDG PET/CT scans were performed in 4 patients (3 males, 1 female; median age: 53.5 years, range: 52-73 years). Of 9 PET/CT scans, 2 scans were done for initial staging, 2 for restaging, and 5 for evaluation of treatment response. PET/CT image interpretation and analysis was performed qualitatively (visually) and semiquantitatively. Absence of uptake in postchemotherapy PET/CT scan was considered as complete response and a fall in SUV by more than 50% of baseline value, as significant response. Patients 1 and 2 underwent staging FDG PET/CT. Patient 1 had undergone left radical nephrectomy 13 years back for left-sided RCC. Current FDG PET/CT revealed appearance of right RCC with adrenal metastasis. PET/CT of patient 2 demonstrated right adrenal and distant metastases. PET/CT done for restaging in patient 3, revealed right adrenal and abdominal lymph nodal metastasis. In patient 4, PET/CT revealed solitary adrenal metastasis. Magnetic resonance imaging findings were consistent with adrenal metastasis in this patient. Patient 1 received sunitinib and interferon chemotherapy along with radiotherapy and showed partial response on PET/CT scans done at 6, 17, 23, and 33 months from the initial study. PET/CT of patient 3 demonstrated the progression of disease (nonresponder). FDG PET/CT appears to be useful for staging, treatment response evaluation, and recurrence detection in patients with RCC having adrenal metastasis.
    Clinical nuclear medicine 07/2011; 36(7):513-7. DOI:10.1097/RLU.0b013e3182175435 · 2.86 Impact Factor